Precision BioSciences - DTIL

Discussion in 'Stock Message Boards NYSE, NASDAQ, AMEX' started by Dan Thunderbolt, Sep 3, 2020.

  1. Dan Thunderbolt

    Dan Thunderbolt Well-Known Member

    Joined:
    Aug 26, 2017
    Messages:
    1,088
    Likes Received:
    88
    I have not bought a position yet but I think this is an interesting company with lots of potential, in particular in view of the current share price. Cash is sufficient into 2022.

    Corporate Profile
    Precision BioSciences is dedicated to improving life (DTIL) through its proprietary genome editing platform, “ARCUS.” Precision leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and create healthy and sustainable food and agriculture solutions. Precision is actively developing product candidates in three innovative areas: allogeneic CAR T immunotherapy, in vivo gene correction, and food.
    https://precisionbiosciences.com/precision-corporate-deck/

    Cash and Cash Equivalents: As of June 30, 2020, Precision had approximately $126.9 million in cash and cash equivalents. The Company expects that existing cash, cash equivalents and available credit will be sufficient to fund operating expenses and capital expenditure requirements into 2022.
    https://investor.precisionbioscienc...ciences-reports-second-quarter-2020-financial

    [​IMG]
     
  2. Dan Thunderbolt

    Dan Thunderbolt Well-Known Member

    Joined:
    Aug 26, 2017
    Messages:
    1,088
    Likes Received:
    88
    Defintely looks like it DTIL was trading at its low beginning of September. A missed opportunity...
     

Share This Page